Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 1 4Phase 1/2 3Phase 2 2

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Metastasis Colon Cancer 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 18Irinotecan 16Bevacizumab 12fludarabine 11Nivolumab 11Cetuximab 11Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × Electroporation × Clear all
NCT01939665 2022-12-20

PANFIRE

Amsterdam UMC, location VUmc

Phase 1/2 Completed
50 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03180437 2020-11-02

Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Completed
62 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02718859 2019-09-12

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Completed
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡